PROM1 and cancer: It could potentially minimize the systemic exposure of DOX to sensitive organs in the circulation system, particularly to reduce cardiotoxicity, but allows rapid drug release upon entry of CD133 aptamer-DOX conjugates into the CD133-positive cancer cells.